Cargando…
Identification of a Novel BRAF Thr599dup Mutation in Lung Adenocarcinoma
BRAF mutations are known as oncogenic drivers of non-small cell lung cancer (NSCLC). BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC. Further molecular screening for novel BRAF thr599dup mutation is warranted. The novel BRAF Thr599dup gene mutation, for...
Autores principales: | Zhang, Xuefei, Li, Mo, Lv, Desheng, Sun, Ge, Bai, Yu, Tian, Hui, Liu, Changhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter Open
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046617/ https://www.ncbi.nlm.nih.gov/pubmed/30019008 http://dx.doi.org/10.1515/med-2018-0042 |
Ejemplares similares
-
Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma
por: Miller, Katherine E., et al.
Publicado: (2018) -
Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation
por: Miller, Katherine E., et al.
Publicado: (2021) -
A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker
por: Turshudzhyan, Alla, et al.
Publicado: (2020) -
Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma
por: Pasau, Thomas, et al.
Publicado: (2022) -
MiR‐563 restrains cell proliferation via targeting LIN28B in human lung cancer
por: Zhang, Xuefei, et al.
Publicado: (2019)